Cold Sores News and Research

RSS

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

AVANIR Pharmaceuticals, Inc. today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) announcing that it intends to grant the Company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia™ well into 2025.

8 Oct 2009

Research must focus on discovering potential causes and treatments for Bell's palsy

Drugs widely prescribed to treat facial paralysis in Bell's palsy are ineffective and are based on false notions of the cause of the condition, according to Cochrane Researchers. They say research must now focus on discovering other potential causes and treatments.

7 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

Clinical trial data of Lipsovir presented at ICAAC

Medivir presented Lipsovir (ME-609) at a poster session on 14th September at the ongoing ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting.

16 Sep 2009

NanoBio presents preclinical data of NB-201 for treating burn wounds at the 2009 ICAAC

NanoBio Corporation today announced compelling preclinical data for NB-201, a nanoemulsion-based topical lotion for the treatment of burn wounds. In preclinical studies, NB-201 dramatically reduced the severity of burn wound infections as well as inflammation following thermal injuries. The research was conducted at the University of Michigan Medical School in Ann Arbor as a collaborative effort between the University and NanoBio.

15 Sep 2009

Oil-and-water-based nanoemulsion could be more effective for treating burns

Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies.

15 Sep 2009

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns.

9 Sep 2009

NanoViricides' drug pipeline to be discussed at NanoBusiness2009

NanoViricides, Inc. (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been asked to present a talk at NanoBusiness2009 - the 8th annual NanoBusiness Conference.

8 Sep 2009

AVANIR raises funds to develop and commercialize Zenvia for PBA

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced it had raised gross proceeds of approximately $10.6 million via the sale of approximately 4.5 million shares of common stock at a weighted average price of $2.34 per share.

28 Aug 2009

Nanoviricides herpes study discussed on CBS News report

NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.

12 Aug 2009

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

US FDA approves Lipsovir for cold sores

The US Food and Drug Administration (FDA) has now approved Lipsovir, i.e. granted Medivir's New Drug Application (NDA) for the use of acyclovir and hydrocortisone for early treatment of recurrent cold sores to decreases the risk of cold sores, and to shorten the healing time for those cold sores which are not prevented.

3 Aug 2009

Immune cells in skin fight off infection better than the rest

Scientists at the University of Melbourne have discovered the local action of immune cells in the skin, which could improve treatment of viral skin infections.

8 Apr 2009

Discovery of protein that reactivates latent herpes simplex virus

Research in Public Library of Science (PLoS) Pathogens appears to solve a long standing medical mystery by identifying a viral protein, VP16, as the molecular key that prompts herpes simplex virus (HSV) to exit latency and cause recurrent disease.

29 Mar 2009

Discovery of cellular process that fights type 1 herpes simplex

Scientists have discovered a new way for our immune system to combat the elusive virus responsible for cold sores: Type 1 herpes simplex (HSV-1).

23 Mar 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

Super-fine oil-and-water emulsion protects against superbugs that kill cystic fibrosis patients

University of Michigan scientists report highly encouraging evidence that a super-fine oil-and-water emulsion, already shown to kill many other microbes, may be able to quell the ravaging, often drug-resistant infections that cause nearly all cystic fibrosis deaths.

5 Feb 2009

Gene-targeting approach for herpes treatment

A new therapy being developed at the University of Florida could, in time, produce another weapon for the fight against herpes.

3 Feb 2009